B-intervention	0	10	Ribociclib
O	11	13	as
O	14	19	First
O	19	20	-
O	20	24	Line
O	25	32	Therapy
O	33	36	for
O	37	39	HR
O	39	40	-
O	40	48	Positive
O	48	49	,
O	50	58	Advanced
O	59	65	Breast
O	66	72	Cancer
O	72	73	.

O	74	77	The
O	78	88	inhibition
O	89	91	of
O	92	98	cyclin
O	98	99	-
O	99	108	dependent
O	109	116	kinases
O	117	118	4
O	119	122	and
O	123	124	6
O	125	126	(
O	126	130	CDK4
O	130	131	/
O	131	132	6
O	132	133	)
O	134	139	could
O	140	151	potentially
O	152	160	overcome
O	161	163	or
O	164	169	delay
O	170	180	resistance
O	181	183	to
O	184	193	endocrine
O	194	201	therapy
O	202	204	in
O	205	213	advanced
O	214	220	breast
O	221	227	cancer
O	228	232	that
O	233	235	is
O	236	244	positive
O	245	248	for
O	249	256	hormone
O	257	265	receptor
O	266	267	(
O	267	269	HR
O	269	270	)
O	271	274	and
O	275	283	negative
O	284	287	for
O	288	293	human
O	294	303	epidermal
O	304	310	growth
O	311	317	factor
O	318	326	receptor
O	327	328	2
O	329	330	(
O	330	334	HER2
O	334	335	)
O	335	336	.

O	337	339	In
O	340	344	this
O	345	355	randomized
O	355	356	,
O	357	364	placebo
O	364	365	-
O	365	375	controlled
O	375	376	,
O	377	382	phase
O	383	384	3
O	385	390	trial
O	390	391	,
O	392	394	we
O	395	404	evaluated
O	405	408	the
O	409	417	efficacy
O	418	421	and
O	422	428	safety
O	429	431	of
O	432	435	the
O	436	445	selective
O	446	450	CDK4
O	450	451	/
O	451	452	6
O	453	462	inhibitor
O	463	473	ribociclib
O	474	482	combined
O	483	487	with
O	488	497	letrozole
O	498	501	for
O	502	507	first
O	507	508	-
O	508	512	line
O	513	522	treatment
O	523	525	in
B-total-participants	526	529	668
O	530	544	postmenopausal
O	545	550	women
O	551	555	with
O	556	558	HR
O	558	559	-
O	559	567	positive
O	567	568	,
O	569	573	HER2
O	573	574	-
O	574	582	negative
O	583	592	recurrent
O	593	595	or
O	596	606	metastatic
O	607	613	breast
O	614	620	cancer
O	621	624	who
O	625	628	had
O	629	632	not
O	633	641	received
O	642	650	previous
O	651	659	systemic
O	660	667	therapy
O	668	671	for
O	672	680	advanced
O	681	688	disease
O	688	689	.

O	690	692	We
O	693	701	randomly
O	702	710	assigned
O	711	714	the
O	715	723	patients
O	724	726	to
O	727	734	receive
O	735	741	either
O	742	752	ribociclib
O	753	754	(
O	754	757	600
O	758	760	mg
O	761	764	per
O	765	768	day
O	769	771	on
O	772	773	a
O	774	775	3
O	775	776	-
O	776	781	weeks
O	781	782	-
O	782	784	on
O	784	785	,
O	786	787	1
O	787	788	-
O	788	792	week
O	792	793	-
O	793	796	off
O	797	805	schedule
O	805	806	)
O	807	811	plus
O	812	821	letrozole
O	822	823	(
O	823	824	2
O	824	825	.
O	825	826	5
O	827	829	mg
O	830	833	per
O	834	837	day
O	837	838	)
O	839	841	or
B-control	842	849	placebo
I-control	850	854	plus
I-control	855	864	letrozole
O	864	865	.

O	866	869	The
O	870	877	primary
O	878	881	end
O	882	887	point
O	888	891	was
O	892	904	investigator
O	904	905	-
O	905	913	assessed
B-outcome-Measure	914	925	progression
I-outcome-Measure	925	926	-
I-outcome-Measure	926	930	free
I-outcome-Measure	931	939	survival
O	939	940	.

O	941	950	Secondary
O	951	954	end
O	955	961	points
O	962	970	included
B-outcome-Measure	971	978	overall
I-outcome-Measure	979	987	survival
O	987	988	,
B-outcome-Measure	989	996	overall
I-outcome-Measure	997	1005	response
I-outcome-Measure	1006	1010	rate
O	1010	1011	,
O	1012	1015	and
B-outcome-Measure	1016	1022	safety
O	1022	1023	.

O	1024	1025	A
O	1026	1036	preplanned
O	1037	1044	interim
O	1045	1053	analysis
O	1054	1057	was
O	1058	1067	performed
O	1068	1070	on
O	1071	1078	January
O	1079	1081	29
O	1081	1082	,
O	1083	1087	2016
O	1087	1088	,
O	1089	1094	after
O	1095	1098	243
O	1099	1107	patients
O	1108	1111	had
O	1112	1119	disease
O	1120	1131	progression
O	1132	1134	or
O	1135	1139	died
O	1139	1140	.

O	1141	1153	Prespecified
O	1154	1162	criteria
O	1163	1166	for
O	1167	1178	superiority
O	1179	1187	required
O	1188	1189	a
O	1190	1196	hazard
O	1197	1202	ratio
O	1203	1205	of
O	1206	1207	0
O	1207	1208	.
O	1208	1210	56
O	1211	1213	or
O	1214	1218	less
O	1219	1223	with
O	1224	1225	P
O	1225	1226	<
O	1226	1227	1
O	1227	1228	.
O	1228	1230	29
O	1230	1231	×
O	1231	1233	10
O	1233	1234	-
O	1234	1235	5
O	1235	1236	.

O	1237	1240	The
O	1241	1249	duration
O	1250	1252	of
O	1253	1264	progression
O	1264	1265	-
O	1265	1269	free
O	1270	1278	survival
O	1279	1282	was
O	1283	1296	significantly
O	1297	1303	longer
O	1304	1306	in
O	1307	1310	the
O	1311	1321	ribociclib
O	1322	1327	group
O	1328	1332	than
O	1333	1335	in
O	1336	1339	the
O	1340	1347	placebo
O	1348	1353	group
O	1354	1355	(
O	1355	1361	hazard
O	1362	1367	ratio
O	1367	1368	,
O	1369	1370	0
O	1370	1371	.
O	1371	1373	56
O	1373	1374	;
O	1375	1377	95
O	1377	1378	%
O	1379	1381	CI
O	1381	1382	,
O	1383	1384	0
O	1384	1385	.
O	1385	1387	43
O	1388	1390	to
O	1391	1392	0
O	1392	1393	.
O	1393	1395	72
O	1395	1396	;
O	1397	1398	P
O	1398	1399	=
O	1399	1400	3
O	1400	1401	.
O	1401	1403	29
O	1403	1404	×
O	1404	1406	10
O	1406	1407	-
O	1407	1408	6
O	1409	1412	for
O	1413	1424	superiority
O	1424	1425	)
O	1425	1426	.

O	1427	1430	The
O	1431	1437	median
O	1438	1446	duration
O	1447	1449	of
O	1450	1456	follow
O	1456	1457	-
O	1457	1459	up
O	1460	1463	was
O	1464	1466	15
O	1466	1467	.
O	1467	1468	3
O	1469	1475	months
O	1475	1476	.

O	1477	1482	After
B-outcome	1483	1485	18
I-outcome	1486	1492	months
O	1492	1493	,
O	1494	1497	the
B-outcome	1498	1509	progression
I-outcome	1509	1510	-
I-outcome	1510	1514	free
I-outcome	1515	1523	survival
I-outcome	1524	1528	rate
O	1529	1532	was
B-iv-bin-percent	1533	1535	63
I-iv-bin-percent	1535	1536	.
I-iv-bin-percent	1536	1537	0
I-iv-bin-percent	1537	1538	%
O	1539	1540	(
O	1540	1542	95
O	1542	1543	%
O	1544	1554	confidence
O	1555	1563	interval
O	1564	1565	[
O	1565	1567	CI
O	1567	1568	]
O	1568	1569	,
O	1570	1572	54
O	1572	1573	.
O	1573	1574	6
O	1575	1577	to
O	1578	1580	70
O	1580	1581	.
O	1581	1582	3
O	1582	1583	)
O	1584	1586	in
O	1587	1590	the
O	1591	1601	ribociclib
O	1602	1607	group
O	1608	1611	and
B-cv-bin-percent	1612	1614	42
I-cv-bin-percent	1614	1615	.
I-cv-bin-percent	1615	1616	2
I-cv-bin-percent	1616	1617	%
O	1618	1619	(
O	1619	1621	95
O	1621	1622	%
O	1623	1625	CI
O	1625	1626	,
O	1627	1629	34
O	1629	1630	.
O	1630	1631	8
O	1632	1634	to
O	1635	1637	49
O	1637	1638	.
O	1638	1639	5
O	1639	1640	)
O	1641	1643	in
O	1644	1647	the
O	1648	1655	placebo
O	1656	1661	group
O	1661	1662	.

O	1663	1665	In
O	1666	1674	patients
O	1675	1679	with
O	1680	1690	measurable
O	1691	1698	disease
O	1699	1701	at
O	1702	1710	baseline
O	1710	1711	,
O	1712	1715	the
B-outcome	1716	1723	overall
I-outcome	1724	1732	response
I-outcome	1733	1737	rate
O	1738	1741	was
B-iv-bin-percent	1742	1744	52
I-iv-bin-percent	1744	1745	.
I-iv-bin-percent	1745	1746	7
I-iv-bin-percent	1746	1747	%
O	1748	1751	and
B-cv-bin-percent	1752	1754	37
I-cv-bin-percent	1754	1755	.
I-cv-bin-percent	1755	1756	1
I-cv-bin-percent	1756	1757	%
O	1757	1758	,
O	1759	1771	respectively
O	1772	1773	(
O	1773	1774	P
O	1774	1775	<
O	1775	1776	0
O	1776	1777	.
O	1777	1780	001
O	1780	1781	)
O	1781	1782	.

O	1783	1789	Common
B-outcome	1790	1795	grade
I-outcome	1796	1797	3
I-outcome	1798	1800	or
I-outcome	1801	1802	4
I-outcome	1803	1810	adverse
I-outcome	1811	1817	events
O	1818	1822	that
O	1823	1827	were
O	1828	1836	reported
O	1837	1839	in
O	1840	1844	more
O	1845	1849	than
O	1850	1852	10
O	1852	1853	%
O	1854	1856	of
O	1857	1860	the
O	1861	1869	patients
O	1870	1872	in
O	1873	1879	either
O	1880	1885	group
O	1886	1890	were
B-outcome	1891	1902	neutropenia
O	1903	1904	(
B-iv-bin-percent	1904	1906	59
I-iv-bin-percent	1906	1907	.
I-iv-bin-percent	1907	1908	3
I-iv-bin-percent	1908	1909	%
O	1910	1912	in
O	1913	1916	the
O	1917	1927	ribociclib
O	1928	1933	group
O	1934	1936	vs
O	1936	1937	.
B-cv-bin-percent	1938	1939	0
I-cv-bin-percent	1939	1940	.
I-cv-bin-percent	1940	1941	9
I-cv-bin-percent	1941	1942	%
O	1943	1945	in
O	1946	1949	the
O	1950	1957	placebo
O	1958	1963	group
O	1963	1964	)
O	1965	1968	and
B-outcome	1969	1979	leukopenia
O	1980	1981	(
B-iv-bin-percent	1981	1983	21
I-iv-bin-percent	1983	1984	.
I-iv-bin-percent	1984	1985	0
I-iv-bin-percent	1985	1986	%
O	1987	1989	vs
O	1989	1990	.
B-cv-bin-percent	1991	1992	0
I-cv-bin-percent	1992	1993	.
I-cv-bin-percent	1993	1994	6
I-cv-bin-percent	1994	1995	%
O	1995	1996	)
O	1996	1997	;
O	1998	2001	the
B-outcome	2002	2007	rates
I-outcome	2008	2010	of
I-outcome	2011	2026	discontinuation
I-outcome	2027	2034	because
I-outcome	2035	2037	of
I-outcome	2038	2045	adverse
I-outcome	2046	2052	events
O	2053	2057	were
B-iv-bin-percent	2058	2059	7
I-iv-bin-percent	2059	2060	.
I-iv-bin-percent	2060	2061	5
I-iv-bin-percent	2061	2062	%
O	2063	2066	and
B-cv-bin-percent	2067	2068	2
I-cv-bin-percent	2068	2069	.
I-cv-bin-percent	2069	2070	1
I-cv-bin-percent	2070	2071	%
O	2071	2072	,
O	2073	2085	respectively
O	2085	2086	.

O	2087	2092	Among
O	2093	2101	patients
O	2102	2111	receiving
O	2112	2119	initial
O	2120	2128	systemic
O	2129	2138	treatment
O	2139	2142	for
O	2143	2145	HR
O	2145	2146	-
O	2146	2154	positive
O	2154	2155	,
O	2156	2160	HER2
O	2160	2161	-
O	2161	2169	negative
O	2170	2178	advanced
O	2179	2185	breast
O	2186	2192	cancer
O	2192	2193	,
O	2194	2197	the
O	2198	2206	duration
O	2207	2209	of
O	2210	2221	progression
O	2221	2222	-
O	2222	2226	free
O	2227	2235	survival
O	2236	2239	was
O	2240	2253	significantly
O	2254	2260	longer
O	2261	2266	among
O	2267	2272	those
O	2273	2282	receiving
O	2283	2293	ribociclib
O	2294	2298	plus
O	2299	2308	letrozole
O	2309	2313	than
O	2314	2319	among
O	2320	2325	those
O	2326	2335	receiving
O	2336	2343	placebo
O	2344	2348	plus
O	2349	2358	letrozole
O	2358	2359	,
O	2360	2364	with
O	2365	2366	a
O	2367	2373	higher
O	2374	2378	rate
O	2379	2381	of
O	2382	2398	myelosuppression
O	2399	2401	in
O	2402	2405	the
O	2406	2416	ribociclib
O	2417	2422	group
O	2422	2423	.

O	2424	2425	(
O	2425	2431	Funded
O	2432	2434	by
O	2435	2443	Novartis
O	2444	2459	Pharmaceuticals
O	2459	2460	;
O	2461	2475	ClinicalTrials
O	2475	2476	.
O	2477	2480	gov
O	2481	2487	number
O	2487	2488	,
O	2489	2500	NCT01958021
O	2501	2502	.
O	2502	2503	)
O	2503	2504	.
